Physician profile
Kyle D Brown
NPI 1326651928
$648.75
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $99.35 · 2024: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $162.50 | 2024 | |
| Boston Scientific Corporation | $125.60 | 2021-2022 | |
| Amgen INC. | $60.48 | 2021 | |
| Upsher-Smith Laboratories LLC | $52.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $44.82 | 2021 | |
| Uswm, LLC | $37.06 | 2021 | |
| Amneal Pharmaceuticals LLC | $34.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.87 | 2021 | |
| Abbvie INC. | $16.26 | 2021 | |
| Indivior INC. | $15.39 | 2021 | |
| Biodelivery Sciences International, INC. | $13.04 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.